See more : DWS Group GmbH & Co. KGaA (DWS.DE) Income Statement Analysis – Financial Results
Complete financial analysis of Creso Pharma Limited (CPH.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Creso Pharma Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Sac’s Bar Holdings Inc. (9990.T) Income Statement Analysis – Financial Results
- Fastned B.V. (FAST.AS) Income Statement Analysis – Financial Results
- MSP Recovery, Inc. (MSPRZ) Income Statement Analysis – Financial Results
- Exlites Holdings International, Inc. (EXHI) Income Statement Analysis – Financial Results
- Sonoro Gold Corp. (SMOFF) Income Statement Analysis – Financial Results
Creso Pharma Limited (CPH.AX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cresopharma.com
About Creso Pharma Limited
Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates, processes, and sells cannabis products, as well as supplies cannabis retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.69M | 6.22M | 2.45M | 3.63M | 578.22K | 243.80K | 8.02K |
| Cost of Revenue | 8.40M | 6.62M | 6.33M | 1.50M | 353.57K | 437.70K | 32.83K |
| Gross Profit | 287.00K | -400.61K | -3.88M | 2.13M | 224.66K | -193.90K | -24.81K |
| Gross Profit Ratio | 3.30% | -6.44% | -158.61% | 58.62% | 38.85% | -79.53% | -309.22% |
| Research & Development | 0.00 | 0.00 | 344.99K | 286.03K | 286.54K | 788.62K | 488.98K |
| General & Administrative | 6.21M | 4.35M | 3.26M | 5.64M | 10.84M | 5.20M | 2.40M |
| Selling & Marketing | 1.68M | 5.84M | 986.18K | 698.00K | 1.23M | 1.83M | 238.23K |
| SG&A | 7.90M | 10.19M | 4.25M | 6.34M | 12.07M | 7.02M | 2.64M |
| Other Expenses | 11.58M | 17.76M | 5.89M | 5.68M | 62.96K | -56.03K | -26.71K |
| Operating Expenses | 19.48M | 27.95M | 10.49M | 12.30M | 16.42M | 13.85M | 4.16M |
| Cost & Expenses | 27.88M | 34.57M | 16.82M | 13.80M | 15.32M | 14.29M | 4.19M |
| Interest Income | 84.00K | 1.00 | 317.00 | 57.09K | 144.04K | 98.45K | 6.50K |
| Interest Expense | 692.00K | 1.71M | 9.27M | 2.09M | 432.22K | 0.00 | 36.75K |
| Depreciation & Amortization | 1.95M | 266.15K | 352.43K | 401.67K | 38.72K | 6.64K | 1.32K |
| EBITDA | -17.62M | -28.06M | -16.49M | -9.81M | -15.95M | -12.96M | -4.20M |
| EBITDA Ratio | -202.76% | -451.22% | -673.55% | -270.44% | -2,758.27% | -5,317.38% | -52,374.28% |
| Operating Income | -19.57M | -28.32M | -16.84M | -10.21M | -15.99M | -12.97M | -4.20M |
| Operating Income Ratio | -225.19% | -455.50% | -687.95% | -281.51% | -2,764.97% | -5,320.10% | -52,390.71% |
| Total Other Income/Expenses | -13.21M | -1.71M | -13.94M | -5.13M | -858.05K | -2.11M | -381.46K |
| Income Before Tax | -32.78M | -30.03M | -30.78M | -15.34M | -16.85M | -15.08M | -4.58M |
| Income Before Tax Ratio | -377.26% | -482.94% | -1,257.46% | -423.00% | -2,913.36% | -6,183.84% | -57,145.84% |
| Income Tax Expense | 2.00K | 1.73M | 6.80M | 1.71M | 336.18K | 975.65K | 10.04K |
| Net Income | -32.78M | -31.77M | -37.58M | -17.05M | -16.76M | -15.08M | -4.58M |
| Net Income Ratio | -377.28% | -510.84% | -1,535.17% | -470.25% | -2,897.86% | -6,183.84% | -57,145.84% |
| EPS | -0.02 | -0.03 | -0.10 | -0.12 | -0.15 | -0.18 | -0.14 |
| EPS Diluted | -0.02 | -0.03 | -0.10 | -0.12 | -0.15 | -0.18 | -0.14 |
| Weighted Avg Shares Out | 1.46B | 1.11B | 370.84M | 143.78M | 112.55M | 83.14M | 31.79M |
| Weighted Avg Shares Out (Dil) | 1.46B | 1.11B | 370.84M | 143.78M | 112.55M | 83.14M | 31.79M |
Source: https://incomestatements.info
Category: Stock Reports